PAVmed reported a Q2 2026 GAAP loss per share of $0.87 and a non-GAAP loss of $0.27, beating analyst expectations of a $0.47 loss. Revenue was $33,000, below the $49,000 consensus. Lucid Diagnostics, an investment of PAVmed, generated $1.5 million in revenue and expanded insurance coverage for its EsoGuard test. Veris Health, part of PAVmed, is developing an implantable monitor with FDA submission planned for early 2027. The company ended the quarter with $3.8 million in cash but remains unprofitable.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...
Seaport Global raised the price target for Madison Square Garden Sports Corp. to $473, reflecting a 17.13% potential upside. The company reported strong fiscal Q4 results with earnings per share of $1.19, beating estimates of $0.72, and revenue risin...
Airbus is outperforming Boeing in commercial aircraft orders, securing 821 net orders in H1 2026 compared to Boeing's 408. Morgan Stanley maintains an "Overweight" rating on Airbus, raising its price target to €255, reflecting confidence in the compa...
Target is expected to report second-quarter earnings of $2.25 per share, a 9.8% increase from last year, with revenues projected at $26.06 billion, up 3.4%. Despite these positive forecasts, the stock has surged 57% year-to-date, leading an analyst t...
